CGMP signals modulate camp levels in a compartment-specific manner to regulate catecholamine-dependent signaling in cardiac myocytes

Circulation Research

Volumn 108, Issue 8, 2011, Pages 929-939

  Stangherlin, Alessandra ^a   Gesellchen, Frank ^a   Zoccarato, Anna ^a   Terrin, Anna ^a   Fields, Laura Ashley ^a   Berrera, Marco ^a   Surdo, Nicoletta Concetta ^a   Craig, Margaret Anne ^b   Smith, Godfrey ^b   Hamilton, Graham ^a   Zaccolo, Manuela ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

ANP; cAMP; cGMP; nitric oxide; signal transduction

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE REGULATORY SUBUNIT IALPHA; CYCLIC AMP DEPENDENT PROTEIN KINASE REGULATORY SUBUNIT IIALPHA; CYCLIC GMP; CYCLIC NUCLEOTIDE; ISOPRENALINE; PHOSPHODIESTERASE III; SPLEEN EXONUCLEASE;

ADRENERGIC SYSTEM; ANIMAL CELL; ARTICLE; BIOSENSOR; FLUORESCENCE RESONANCE ENERGY TRANSFER; HEART MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT;

ANIMALS; CATECHOLAMINES; CELLS, CULTURED; CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 2; MYOCYTES, CARDIAC; RATS; SIGNAL TRANSDUCTION;

EID: 79954891242     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.110.230698     Document Type: Article

References (48)

1. El-Armouche A, Eschenhagen T. Beta-adrenergic stimulation and myocardial function in the failing heart. Heart Fail Rev. 2009;14: 225-241.
2. Shah AM, MacCarthy PA. Paracrine and autocrine effects of nitric oxide on myocardial function. Pharmacol Ther. 2000;86:49-86. (Pubitemid 30173144)
3. Rosenkranz AC, Woods RL, Dusting GJ, Ritchie RH. Antihypertrophic actions of the natriuretic peptides in adult rat cardiomyocytes: importance of cyclic GMP. Cardiovasc Res. 2003;57:515-522. (Pubitemid 36144228)
4. Felker GM, Pang PS, Adams KF, Cleland JG, Cotter G, Dickstein K, Filippatos GS, Fonarow GC, Greenberg BH, Hernandez AF, Khan S, Komajda M, Konstam MA, Liu PP, Maggioni AP, Massie BM, McMurray JJ, Mehra M, Metra M, O'Connell J, O'Connor CM, Pina IL, Ponikowski P, Sabbah HN, Teerlink JR, Udelson JE, Yancy CW, Zannad F, Gheorghiade M. Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. Circ Heart Fail. 2010;3:314-325.
5. Nony P, Boissel JP, Lievre M, Leizorovicz A, Haugh MC, Fareh S, de Breyne B. Evaluation of the effect of phosphodiesterase inhibitors on mortality in chronic heart failure patients. A meta-analysis. Eur J Clin Pharmacol. 1994;46:191-196. (Pubitemid 24137425)
6. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation. 1996;94: 2807-2816. (Pubitemid 26411745)
7. Steinberg SF, Brunton LL. Compartmentation of G protein-coupled signaling pathways in cardiac myocytes. Annu Rev Pharmacol Toxicol. 2001;41:751-773. (Pubitemid 32385905)
8. Zaccolo M, Pozzan T. Discrete microdomains with high concentration of cAMP in stimulated rat neonatal cardiac myocytes. Science. 2002;295: 1711-1715. (Pubitemid 34202906)
9. Zaccolo M. cAMP signal transduction in the heart: understanding spatial control for the development of novel therapeutic strategies. Br J Pharmacol. 2009;158:50-60.
10. Movsesian MA, Bristow MR. Alterations in cAMP-mediated signaling and their role in the pathophysiology of dilated cardiomyopathy. Curr Top Dev Biol. 2005;68:25-48. (Pubitemid 43588862)
11. Corbin JD, Sugden PH, Lincoln TM, Keely SL. Compartmentalization of adenosine 3:5-monophosphate and adenosine 3:5-monophosphatedependent protein kinase in heart tissue. J Biol Chem. 1977;252: 3854-3861. (Pubitemid 8127237)
12. Di Benedetto G, Zoccarato A, Lissandron V, Terrin A, Li X, Houslay MD, Baillie GS, Zaccolo M. Protein kinase A type I and type II define distinct intracellular signaling compartments. Circ Res. 2008;103: 836-844.
13. Scott JD, Santana LF. A-kinase anchoring proteins: getting to the heart of the matter. Circulation. 2010;121:1264-1271.
14. Carr DW, Stofko-Hahn RE, Fraser ID, Bishop SM, Acott TS, Brennan RG, Scott JD. Interaction of the regulatory subunit (RII) of cAMPdependent protein kinase with RII-anchoring proteins occurs through an amphipathic helix binding motif. J Biol Chem. 1991;266: 14188-14192. (Pubitemid 21907482)
15. Su J, Scholz PM, Weiss HR. Differential effects of cGMP produced by soluble and particulate guanylyl cyclase on mouse ventricular myocytes. Exp Biol Med (Maywood). 2005;230:242-250. (Pubitemid 40478248)
16. Castro LR, Verde I, Cooper DM, Fischmeister R. Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes. Circulation. 2006;113:2221-2228.
17. Houslay MD. Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. Trends Biochem Sci. 2010;35:91-100.
18. Conti M, Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem. 2007;76:481-511.
19. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther. 2006;109:366-398. (Pubitemid 43132818)
20. Mongillo M, McSorley T, Evellin S, Sood A, Lissandron V, Terrin A, Huston E, Hannawacker A, Lohse MJ, Pozzan T, Houslay MD, Zaccolo M. Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ Res. 2004; 95:67-75. (Pubitemid 38931837)
21. Mongillo M, Tocchetti CG, Terrin A, Lissandron V, Cheung YF, Dostmann WR, Pozzan T, Kass DA, Paolocci N, Houslay MD, Zaccolo M. Compartmentalized phosphodiesterase-2 activity blunts betaadrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ Res. 2006;98:226-234.
22. Zaccolo M, Movsesian MA. cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology. Circ Res. 2007;100:1569-1578. (Pubitemid 46897260)
23. Martinez SE, Beavo JA, Hol WG. GAF domains: two-billion-year-old molecular switches that bind cyclic nucleotides. Mol Intervent. 2002;2: 317-323.
24. Michie AM, Lobban M, Muller T, Harnett MM, Houslay MD. Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram. Cell Signal. 1996;8:97-110.
25. Shakur Y, Holst LS, Landstrom TR, Movsesian M, Degerman E, Manganiello V. Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family. Prog Nucleic Acid Res Mol Biol. 2001;66: 241-277.
26. Maurice DH. Cyclic nucleotide phosphodiesterase-mediated integration of cGMP and cAMP signaling in cells of the cardiovascular system. Front Biosci. 2005;10:1221-1228.
27. Zaccolo M. Use of chimeric fluorescent proteins and fluorescence resonance energy transfer to monitor cellular responses. Circ Res. 2004;94: 866-873. (Pubitemid 38490063)
28. Honda A, Adams SR, Sawyer CL, Lev-Ram V, Tsien RY, Dostmann WR. Spatiotemporal dynamics of guanosine 3, 5-cyclic monophosphate revealed by a genetically encoded, fluorescent indicator. Proc Natl Acad Sci USA. 2001;98:2437-2442. (Pubitemid 32209500)
29. Nikolaev VO, Bunemann M, Hein L, Hannawacker A, Lohse MJ. Novel single chain cAMP sensors for receptor-induced signal propagation. J Biol Chem. 2004;279:37215-37218. (Pubitemid 39195424)
30. McCahill A, McSorley T, Huston E, Hill EV, Lynch MJ, Gall I, Keryer G, Lygren B, Tasken K, Van Heeke G, Houslay MD. In resting COS1 cells a dominant negative approach shows that specific, anchored PDE4 cAMP phosphodiesterase isoforms gate the activation, by basal cyclic AMP production, of AKAP-tethered protein kinase A type II located in the centrosomal region. Cell Signal. 2005;17: 1158-1173. (Pubitemid 40933535)
31. Wu AY, Tang XB, Martinez SE, Ikeda K, Beavo JA. Molecular determinants for cyclic nucleotide binding to the regulatory domains of phosphodiesterase 2A. J Biol Chem. 2004;279:37928-37938. (Pubitemid 39195508)
32. Allen MD, DiPilato LM, Rahdar M, Ren YR, Chong C, Liu JO, Zhang J. Reading dynamic kinase activity in living cells for high-throughput screening. ACS Chem Biol. 2006;1:371-376.
33. Maurice DH, Palmer D, Tilley DG, Dunkerley HA, Netherton SJ, Raymond DR, Elbatarny HS, Jimmo SL. Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol Pharmacol. 2003;64:533-546. (Pubitemid 37048555)
34. Surapisitchat J, Jeon KI, Yan C, Beavo JA. Differential regulation of endothelial cell permeability by cGMP via phosphodiesterases 2 and 3. Circ Res. 2007;101:811-818. (Pubitemid 350287196)
35. Seddon M, Shah AM, Casadei B. Cardiomyocytes as effectors of nitric oxide signalling. Cardiovasc Res. 2007;75:315-326. (Pubitemid 46961933)
36. Shah AM, Spurgeon HA, Sollott SJ, Talo A, Lakatta EG. 8-bromo-cGMP reduces the myofilament response to Ca2 in intact cardiac myocytes. Circ Res. 1994;74:970-978.
37. Balligand JL, Kelly RA, Marsden PA, Smith TW, Michel T. Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc Natl Acad Sci USA. 1993;90:347-351. (Pubitemid 23010307)
38. Vila-Petroff MG, Younes A, Egan J, Lakatta EG, Sollott SJ. Activation of distinct cAMP-dependent and cGMP-dependent pathways by nitric oxide in cardiac myocytes. Circ Res. 1999;84:1020-1031. (Pubitemid 29227681)
39. Ziolo MT, Katoh H, Bers DM. Positive and negative effects of nitric oxide on Ca(2) sparks: influence of beta-adrenergic stimulation. Am J Physiol Heart Circ Physiol. 2001;281:H2295-H2303.
40. Massion PB, Feron O, Dessy C, Balligand JL. Nitric oxide and cardiac function: ten years after, and continuing. Circ Res. 2003;93:388-398 (Pubitemid 37100003)
41. Massion PB, Balligand JL. Modulation of cardiac contraction, relaxation and rate by the endothelial nitric oxide synthase (eNOS): lessons from genetically modified mice. J Physiol. 2003;546:63-75.
42. Stone JA, Backx PH, ter Keurs HE. The effect of atrial natriuretic factor on force development in rat cardiac trabeculae. Can J Physiol Pharmacol. 1990;68:1247-1254.
43. Ohte N, Cheng CP, Suzuki M, Little WC. Effects of atrial natriuretic peptide on left ventricular performance in conscious dogs before and after pacing-induced heart failure. J Pharmacol Exp Ther. 1999;291: 589-595. (Pubitemid 29503529)
44. D'Souza SP, Davis M, Baxter GF. Autocrine and paracrine actions of natriuretic peptides in the heart. Pharmacol Ther. 2004;101:113-129. (Pubitemid 38167564)
45. Garcia-Dorado D, Agullo L, Sartorio CL, Ruiz-Meana M. Myocardial protection against reperfusion injury: the cGMP pathway. Thromb Haemost. 2009;101:635-642.
46. Paulus WJ, Bronzwaer JG. Myocardial contractile effects of nitric oxide. Heart Fail Rev. 2002;7:371-383. (Pubitemid 35396469)
47. Hare JM, Givertz MM, Creager MA, Colucci WS. Increased sensitivity to nitric oxide synthase inhibition in patients with heart failure: potentiation of beta-adrenergic inotropic responsiveness. Circulation. 1998;97:161-166. (Pubitemid 28124673)
48. Bendall JK, Damy T, Ratajczak P, Loyer X, Monceau V, Marty I, Milliez P, Robidel E, Marotte F, Samuel JL, Heymes C. Role of myocardial neuronal nitric oxide synthase-derived nitric oxide in beta-adrenergic hyporesponsiveness after myocardial infarction-induced heart failure in rat. Circulation. 2004;110:2368-2375. (Pubitemid 39407341)